本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 28, 2026 /PRNewswire/ -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone in December 2025 by securing first place among all non-academic institutes in ophthalmology, on the American scholarly analytics platform ScholarGPS, whilst also claiming second place overall among all institutes in the field globally. This is based on data from the last five years evaluated by the platform. The achievement represents a significant breakthrough for the institute, which has steadily built its translational research capabilities and international eminence in ophthalmic research and biopharmaceuticals for nearly three decades. As the research arm of the Singapore National Eye Centre (SNEC), SERI's rise to the summit of global ophthalmology research rankings since 1997 underscores Singapore's growing prominence as a hub for medical research and innovation in the Asia-Pacific region. Recognition validates SERI's research impact and mission ScholarGPS, a leading platform for tracking academic and research performance, evaluates institutions based on various metrics including research output, citation impact, and scholarly influence. SERI's exceptional performance across these indicators reflects the institute's commitment to advancing eye care through cutting-edge research and clinical excellence. Among the consistent body of quality work that contributed to this achievement are research in diabetic retinopathy, ocular surface (dry eye disease), cornea, myopia and glaucoma. Newer areas of impact also include research in artificial intelligence, digital health, and imaging. "This milestone is a testament to the dedication and expertise of our research teams, clinician-scientists, and support staff who have worked tirelessly to advance the frontiers of ophthalmology research," said Professor Jodhbir Mehta, Executive Director at SERI. "Reaching the top of the ScholarGPS rankings validates our mission to translate innovative research into better outcomes for patients with eye diseases, and we look forward to building upon this remarkable achievement in 2026." SERI's success in translational research over the years SERI's cutting-edge translational research is making a real difference for patients today. The areas of impact include new biopharmaceuticals, such as the development of Vabysmo (faricimab), which reduces the number of injections required for patients with diabetic eye diseases and age-related macular degeneration. Patients who previously needed monthly eye injections to maintain their vision can now go for injections every three to four months instead with this treatment. SERI also developed Myopine, a low-dose atropine eye drop for the treatment of childhood myopia. This treatment is now available to patients in multiple countries throughout Asia and the rest of the world. The Institute has also been credited with several device inventions. One of them is the EndoGlide, the world's first US Food and Drug Administration-approved device for advanced corneal endothelial transplant, which is commercially available worldwide. Another device is the Polarisation-Sensitive Optical Coherence Tomography which enables doctors to look at how tissues at the back of the eye affect light's properties on a microscopic level without invasive procedures. This has resulted in the development of a biomarker to track myopia progression. Since two decades ago, SERI had already been at the forefront of integrating artificial intelligence (AI) tools with eye care. Most notably, it created the Singapore Eye Lesion Analyser (SELENA+), an AI software which automatically and accurately detects diabetes-related eye diseases that could lead to blindness if left undiagnosed. Today, SELENA+ is a screening tool used in the Singapore Integrated Diabetic Retinopathy Programme, and Singapore is one of a few countries in the world to have a fully deployed AI screening tool developed by SERI and SNEC. About Singapore Eye Research Institute Established in 1997 as Singapore's national research institute for ophthalmic and vision research, the Singapore Eye Research Institute's (SERI) mission is to conduct high-impact eye research that prevents blindness, low vision and major eye diseases common to Singaporeans and Asians. Over the years, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented around the world. As the research institute of the Singapore National Eye Centre and the largest eye research institute in the Asia Pacific region, SERI collaborates with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes globally. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants. As of December 2024, SERI's faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents. Visit us at www.seri.com.sg. About Singapore National Eye Centre Singapore National Eye Centre (SNEC) was incorporated in 1989 and commenced operations in 1990. It is the designated national centre within Singapore's public sector healthcare network, and spearheads and coordinates the provision of specialised ophthalmological services with emphasis on quality education and research. With 10 subspecialties in ophthalmology, SNEC has achieved rapid growth and currently manages an annual workload of 400,000 outpatient visits and over 30,000 major eye surgeries. Visit us at www.snec.com.sg.
SINGAPORE, Jan. 28, 2026 /PRNewswire/ -- The Republic of Singapore Yacht Club (RSYC), Singapore's oldest club and the first yacht club in Asia, will celebrate 200 years of maritime heritage (#RSYC200) on 7 February 2026 with a Bicentennial Charity Gala Dinner. The event will welcome His Excellency Mr Tharman Shanmugaratnam, President of the Republic of Singapore and Patron of RSYC, as Guest of Honour, and Mr Desmond Lee, Minister for Education, Member of Parliament for West Coast–Jurong West GRC, as an esteemed Honorary Member of RSYC and distinguished guest. With close to 150 guests expected to attend, the evening will bring RSYC's storied past to life, through an exclusive heritage exhibition tracing the Club's evolution across two centuries. A heritage exhibition will showcase immersive displays, rare artefacts and over 80 historic trophies, honouring RSYC's role in shaping Singapore's maritime and sporting culture (Please refer to Appendix A for Programme Flow). This event also supports Singapore's President's Challenge – a national movement launched in 2000 by RSYC's former Patron, the late President S R Nathan, to foster a more caring and cohesive society – and marks the official launch of RSYC's year-long 200th anniversary celebrations, a commemorative series of sporting, social and community events taking place throughout 2026 (Please refer to Appendix B for full list of #RSYC200 events in 2026). An Evening of Grand Stories and Legacy Founded in 1826 as the Singapore Yacht Club, RSYC has evolved alongside the nation's own journey. It received royal patronage from King George V in 1922 and became the Republic of Singapore Yacht Club in 1967 following independence, during which then President of the Republic of Singapore, Mr Yusof bin Ishak, became the first Singaporean Patron, marking a significant milestone for the club. The Club's journey spans royal visits, landmark regattas, wartime sacrifice and post-war renewal. Early visits by HRH Edward, Prince of Wales in 1922, and Queen Elizabeth II in 1953 drew crowds to the waterfront and cemented its long connection to the British Royal Family. During World War II, members served in the Volunteer Forces, and in the years that followed, rebuilt the Club from ruins, shaping an institution defined by resilience. RSYC has witnessed three clubhouses, from Trafalgar Street to Sungei Pandan and today's West Coast home, mirroring Singapore's transformation by its waters. "RSYC's story is deeply intertwined with Singapore's history as a maritime nation. As we mark 200 years, we honour the resilience that shaped our past while looking ahead with confidence to the Club's next chapter," said Commodore Balakrishnan B, Republic of Singapore Yacht Club. Heritage, Reimagined for Today Beyond its heritage, the gala also celebrates RSYC's sporting legacy. The Club has played a central role in developing sailing and rowing in Singapore, with members representing the nation at major international events, including the Olympic Games in Melbourne (1956) and Rome (1960). From its origins as a colonial-era club, RSYC has evolved into a vibrant, multicultural and inclusive community today, reflecting the rich diversity of Singapore. Guests can look forward to an evening of fine dining and live performances, while honouring generations of members, volunteers and staff. Event Details: Date: 7 February 2026 (Saturday) Time: 6pm - 10pm Venue: Republic of Singapore Yacht Club, Nautica Ballroom & RSYC Heritage Gallery Address: 52 West Coast Ferry Road, Singapore 126887 Dress Code: Formal/Black Tie RSVP Details for Media Attendance Members of the media are invited to confirm their attendance for the Bicentennial Charity Gala Dinner latest by 2 February 2026, 12pm SGT. Please RSVP to Diana Estella Peter (diana.estella@rothmanasia.com) or Dionne Hwang (dionne.hwang@rothmanasia.com) with the following details: Name Publication Designation Email Contact No. ### About Republic of Singapore Yacht Club Founded in 1826, the Republic of Singapore Yacht Club (RSYC) is Singapore's oldest yacht club and one of the oldest maritime clubs in Asia. With a rich legacy spanning nearly two centuries, RSYC has played a significant role in shaping Singapore's yachting, maritime and seafaring culture. The Club's first patron was Singapore's inaugural President, Mr Yusof Ishak, marking its longstanding place in the nation's social and historical landscape. Today, RSYC is a premier destination for boating enthusiasts, offering a full suite of marina facilities, berthing services, hospitality amenities and community-centred programmes. Its strategically located marina provides easy access to Singapore's Southern Islands, while its clubhouse features dining, leisure and recreational facilities for members, guests and partners. Committed to fostering camaraderie, sportsmanship and a passion for the sea, RSYC continues to uphold its heritage while evolving to meet the needs of a modern and vibrant yachting community. Find out more at https://rsyc.org.sg/ | Instagram: @rsycsg | Facebook: @rsycsg | LinkedIn: RSYC For media enquiries, please contact: Republic of Singapore Yacht ClubCordelia Liau | Cordelia.Liau@rsyc.org.sg | +65 9116 2405 Rothman & Roman Group Tashan Kassey | tashan.kassey@rothmanasia.com | +65 8282 8746Dionne Hwang | dionne.hwang@rothmanasia.com | +65 8718 6263 Appendix A Programme Flow for the 7 February 2026 Gala Dinner (For media reference only; Not for publication.) • 6.00pm: Registration, welcome reception and whisky tasting• 7.00pm: Arrival of Guest of Honour, President Tharman Shanmugaratnam and official welcome• 7.10pm: RSYC Bicentennial tribute video screening• 7.15pm: Opening address by Commodore, Republic of Singapore Yacht Club• 7.20pm – 7.30pm: Bicentennial plaque unveiling by President Tharman Shanmugaratnam, Mr Desmond Lee, Minister for Education and MP for West Coast–Jurong West GRC, Commodore, and Committee and cake-cutting ceremony• 7.30pm: Dinner service commences (with live string quartet performance)• 7.50pm: Bicentennial Charity Auction (Proceeds benefit The President's Challenge)• 8.15pm: Cheque presentation to the President's Challenge by President Tharman Shanmugaratnam, Mr Desmond Lee, Commodore, and Committee Members• 8.25pm: Presentation of token of appreciation to Guest of Honour• 8.30pm: Departure of Guest of Honour• 8.40pm – 8.50pm: Presentation of token of appreciation and dessert service• 9.00pm – 10.00pm: Post-dinner entertainment and RSYC Heritage Exhibition viewing Appendix B #RSYC200 2026 Events 27 March 2026: Back to School Social NightA nostalgic, adult-themed social evening featuring games, food, and opportunities for members to reconnect 13 June 2026: RSYC Recycled Boat RaceA sustainability-focused team event where participants build and race boats using recycled materials at the RSYC marina 18, 19 & 25 July 2026: RSYC Regatta 2026RSYC's annual sailing regatta featuring keelboats competing in passage and short-course races across Singapore's southern waters 22 & 23 August 2026: RSYC Commodore's Day 2026Annual Open House and celebration welcoming members and the public, featuring water sports, carnival activities, food offerings, and the introduction of new Committee Members 19 & 20 September 2026 (Silver Fleet) and 26 & 27 September 2026 (Gold Fleet): Optimist Knockout Championship 2026A youth sailing championship organised by RSYC under the auspices of the Singapore Sailing Federation 9 October 2026: RSYC Beerfest 2026An evening festival featuring international beers, food, music, and interactive games 18 October 2026: RSYC Fishing Tournament 2026RSYC's annual fishing competition bringing together fishing enthusiasts from across Singapore 14 November 2026: RSYC Charity Cruise 2026A community-focused charity initiative bringing volunteers and sponsors together in support of a meaningful cause 4 & 5 December 2026: Christmas & Boat Light-Up 2026A festive weekend featuring carnival activities, a holiday market, and the Christmas Boat Light-Up Parade 31 December 2026: New Year's Eve Countdown PartyA year-end celebration to welcome the New Year with music, festivities, and fellow members and guests
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Many American users who initially joined Xiaohongshu, a Chinese app for sharing daily life, a year ago following a looming TikTok ban - often referred to as "TikTok refugees" - have become what they now call "Xiaohongshu locals." Netizens from China and the US have used the Chinese social media platform over the past year as an unexpected meeting ground, connecting through family photos, pet videos, and glimpses of ordinary life. Many US users, encountering these fragments of everyday Chinese life for the first time, have started learning about Chinese food and customs. These fragmented posts, carried across digital networks, have fostered closer people-to-people interactions between the two countries. Over time, these interactions have moved beyond curiosity, evolving into understanding, connection, and mutual recognition, producing many heartwarming stories. The Global Times invited three American "Xiaohongshu locals" to share their stories and views. Joseph Noble, an American content creator on social media During a period of uncertainty around TikTok in the US, many creators began to explore different platforms. I saw Xiaohongshu being mentioned frequently and decided to join out of curiosity, but I stayed because I enjoyed the creativity, positivity, and cultural exchange with Chinese netizens. When my first video joking about the TikTok ban and the influx of American users went viral on Xiaohongshu, I immediately started talking to users. It is exciting to see the community built within the comment section and private messages. I have also been lucky enough to make real friendships through this opportunity. I had the privilege to show a friend I met on the app around Los Angeles on her visit to the US. I have discovered Chinese movies, customs, and lifestyles recommended by my friends on social media. I think the first Chinese movie I was introduced to was Nezha. I watched the first one at home dubbed in English and became very excited at news of the second one, which I watched in the theater with the original audio and English subtitles. I have also recommended that film to many friends. I especially love the culture exchange and learning about things I would have never known. For example, I posted a video of me and my mother making hotpot and the comment section explained the proper way to enjoy the meal and educated me on the customs. It is really amazing to see such cultural pride toward things like that. I was familiar with some traditions, such as the Spring Festival, one year ago, but apart from the basics and what media depicted, I did not know much about China. I am so happy to have opened my eyes to such a beautiful way of life filled with thoughtful people. The Chinese netizens have a special way of communicating, joking, and relaxing, and I am so honored to be welcomed into that space. There is a beautiful sense of pride and helpfulness among Chinese netizens that you don't often find in other social media platforms. The interactions and sharing between Chinese and American netizens have been amazing in that they have brought two completely separate communities together, it showed that among the people, we have similar goals; to enjoy the company of those around us and take care of one another. I think it's especially unique as both cultures and peoples have had preconceived notions about each other, but sharing within the same social media platform has taken away the veil and shown how similar the human experience can be. I want every Chinese friend I have met over the past year to know that I appreciate their trust and the community we have built. I read every comment and message I receive. They have helped me see the beauty within myself and feel more confident as a person, and I hope that I have helped them in return. I look forward to all my interactions with them and hope to meet as many as I can as I plan my trip to China. Christy Franklin, a resident of the US state of Wyoming I joined Xiaohongshu a year ago after hearing about it on X. By then, I had already made some online friends from China on X, but that platform is too political. I wanted a place where I could be myself and relax. Another reason for joining was to make more friends, learn about China, its people, its culture and learn Putonghua. Over the past year on the Chinese social media platform, I have made many friends and joined two chat groups dedicated to my favorite Chinese actor Ren Jialun. I have really enjoyed being on the app and visit it almost every day. In some of my posts, I have shared photos from my personal life, such as showing myself, sunset where I live, places I have traveled to, Christmas at my house, and Chinese New Year. With each post, I hope people are getting to know me better. I enjoy looking at posts from other users and friends, especially those showing food, such as bubble tea, and preparation videos of Chinese dishes. There are so many posts about places users have visited in China, showcasing the culture and beautiful scenery. I also appreciate a little humor, such as posts about "Chinese cowboy" and "Chinese Trump." Over the past year, I've had many interactions with Chinese netizens - chatting in group chats and sharing posts, and even having long conversations. With some of them, we've even added each other on WeChat. Many of these friends have been incredibly kind and welcoming, and through our conversations, we've learned a lot about each other. There are several good friends that I met on Chinese social media platform who live in China and have left a deep impression on me. The first person lives in Shanghai and is also a fan of Ren Jialun. Although we followed each other because of our shared interest in celebrities, over the year we have talked about our personal lives, sharing photos and posts, and discussing family and kids. We have complemented, inspired, and given each other advice. This person has answered my questions and shared posts about Chinese culture, suggesting books for me to read. We have also talked about American and Chinese culture, exploring the similarities and differences. After a year, I now see this person as more than just a good friend, but a real sister. She will be the first person I plan to visit when I go to China. The next person is from Jiangsu Province. One day, he offered to get a Kirby plushie for my son since I couldn't find one in the US. I was really touched by his kindness, and I've enjoyed helping his son with English whenever I can. We have done video chats on WeChat, chatting face-to-face online, meeting family members from both our families, and sharing our personal lives and culture. It has been really eye-opening. Since a year ago, my understanding of China and its people has improved. I have found close friends, seen more of the culture, gained more respect and discovered good places to visit. It has been wonderful to see American and Chinese netizens interact in such a natural and friendly way. From what I've seen and experienced, both sides are learning more about each other and gaining humility. Though conversations and posts, it seems that Chinese netizens have learned that some people in the US are not doing as well as they thought and have to struggle with daily life. I think many American netizens are discovering that not everything they have learned about China has been correct. The Chinese people are just like us, living good and peaceful lives. I have seen that Chinese people have love for their home and country. We have different cultures and different ideas, but in the end, we are all the same. I would like to tell my Chinese friends that it has been wonderful during this year, talking, sharing our lives and photos with each other. I hope to make more new friends, continue to talk and share my life with all of you. Brecken Neumann, a resident of the US state of Mississippi I was inspired to join Xiaohongshu during the TikTok ban, seeing everyone promote it as the new place to go. I have always enjoyed Chinese culture and wanted to learn more from people actually living there. At first, I downloaded the app simply out of curiosity - I never expected to receive such enthusiastic interactions from tens of thousands of Chinese netizens. From that moment, opening the app, translating conversations, and laughing with my Chinese friends became a daily routine. They were so sincere. Even casual, curious questions I asked would get many responses, some even with photos to illustrate their answers. Through the Chinese social media platform, we got to know Rongrong and her family. I secretly booked flights to Shanghai for my whole family because we wanted to experience China firsthand and finally meet the friends we had connected with online. Before we landed in Shanghai, I got a haircut and shaved my beard because I wanted to make a good impression on my Chinese friends. The meetings with Rongrong's family still move me emotionally. Seeing how much people were touched by my original post from a year ago was incredible - it was also how Rongrong and I first connected. I reached out to her to let her know the post between our families had gone viral and to prepare for the influx of attention. Meeting Rongrong and her family in China was an amazing experience. I was struck by how friendly, welcoming, and helpful everyone was. It was a very surreal experience then, and it still feels surreal now. During our trip to Shanghai, my daughter grew two new baby teeth, which my wife jokingly pointed out as a symbol of the friendship that had taken root between our families. Now, nothing has changed. We talk every day, whether it's about work, kids' doctor appointments, possible trips, or food. Last year, when we went to the Disney in the US, I remembered our time with Rongrong's family at Shanghai Disney. I missed them and sent gifts to Tiutiu, Rongrong's daughter in China. Later, for my daughter's birthday, Rongrong even sent Hanfu and panda toys all the way from afar, which made us feel even closer. During the New Year, I taught my daughter to say it in Chinese while recording a short video to wish my Chinese friends a happy New Year. We were deeply honored that our meeting in Shanghai drew so much attention from people online. I believe that listening is of great importance, as we are constantly exposed to the pervasive dissemination of information, some of which may be inaccurate. For example, some Western media outlets often downplay China's developmental capabilities in their reports, which is clearly misguided. Before coming to China, we also held certain stereotypes, not based on genuine understanding but rather influenced by secondhand narratives. Now, having actually visited China, I realize how mistaken those perceptions were. The Chinese people I interacted with were friendly, and the country's mobile payment systems and food delivery services are advanced. I could sense that people living in China are directly benefiting from this development. I just want everyone to know how appreciative I am for all the support we've received. I enjoy seeing people share all kinds of things on social media. Let's continue to strive to be kind - because, honestly, this is how the world should be. China truly is a friendly nation, and we made the right choice coming here. I truly hope that everyone is not "led by the nose by certain Western media narratives,'' but instead, see with their own eyes.
IRVINE, Calif., Jan. 27, 2026 /PRNewswire/ -- Aurzen launched Super Bowl Projector Deals for viewers who want a big-screen experience without paying TV-sized prices, offering a more flexible and affordable alternative, backed by verified specs based on real-world testing. Super Bowl has become one of the biggest viewing moments of the year for sports and entertainment fans alike. Whether you're tuning in for the game, the halftime show, or simply gathering friends around good food, one thing is clear: watching on a small screen doesn't quite do the moment justice. Aurzen Roku TV Smart Projector EAZZE D1R Cube U.S.: was US$249.99, now: US$169.99 at Amazon US Canada: CA$195.49 (15% off) at Amazon CA starting February 2 The Roku TV D1R Cube features a built-in Roku TV experience, 1080p resolution, and Dolby Audio in a compact, easy-to-use design. It's a great fit for indoor viewing in dim or moderate lighting, with a sealed optical engine for added durability. Aurzen EAZZE D1 U.S.: US$99.99 (33% off) at Amazon US starting February 2 Canada: was CA$169.99, now: CA$144.49 at Amazon CA With a built-in smart TV and 4K support, the D1 delivers a surprisingly complete big-screen experience for under US$100, making it a solid entry-level option for casual viewing and Super Bowl watch parties. Aurzen EAZZE D1G U.S.: US$169.99 (23% off) at Amazon US starting February 2 Canada: was CA$229.99, now: CA$195.49 at Amazon CA The D1G steps things up with improved brightness and built-in Google TV, making it a better fit for living rooms where you don't want to sit in complete darkness just to see the score. Aurzen BOOM mini U.S.: was US$349.99, now: US$229.99 at Amazon US Canada: CA$288.99 (15% off) at Amazon CA starting February 2 The BOOM mini pairs Google TV with 10W Dolby Audio speakers and 500 ANSI lumens brightness for clear visuals and immersive sound. Its portable design makes it ideal for Super Bowl watch parties at home, in the backyard, or anywhere with a wall to project on. Aurzen BOOM air U.S.: was US$299.99, now: US$179.99 at Amazon US Offering the biggest discount in the lineup, the BOOM air delivers punchy audio in a portable design without the need for extra speakers. USB-C and 65W PD power bank support enable outdoor and on-the-go viewing.
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. Clinical Highlights 2 of 2 evaluable patients enrolled in the Phase 1b trial achieved partial responses One advanced metastatic TNBC patient achieved a confirmed complete metabolic response following re-treatment with pembrolizumab/chemotherapy plus paxalisib (under an expanded access protocol) Responses observed in patients with visceral disease and multi-organ metastases Median time on treatment to date is approximately 6.1 months, with all patients continuing on therapy at the time of this update Paxalisib continues to demonstrate a generally favorable safety and tolerability profile when combined with pembrolizumab and chemotherapy at the 30 mg daily dose The ongoing Phase 1b trial is a multi-center, open-label, randomized study initiated in June 2025 designed to evaluate the safety, tolerability, and preliminary clinical activity of paxalisib in patients with advanced breast cancer, including TNBC, in combination with either: Pembrolizumab plus chemotherapy (current standard-of-care first-line regimen) or Olaparib (advanced breast cancer patients with BRCA mutations). Eligibility for the pembrolizumab-containing cohort required PD-L1–positive disease (CPS ≥10), consistent with standard-of-care practice in metastatic TNBC. Patient 1 – Partial ResponseA 61-year-old female with metastatic TNBC involving the left upper lobe of the lung, initiated treatment with paxalisib (30 mg daily) in combination with pembrolizumab and gemcitabine/carboplatin in June 2025. After nine cycles of therapy, serial imaging demonstrated continued tumor reduction at each assessment, culminating in a partial response by iRECIST criteria. The patient remains active on study. Patient 2 – Partial Response with Complete Resolution of a Target LesionA 47-year-old female with extensively metastatic TNBC involving the lung, liver, bone, and lymph nodes, initiated treatment with paxalisib (30 mg daily) in combination with pembrolizumab and gemcitabine/carboplatin in October 2025. Following three treatment cycles, imaging demonstrated a partial response, including complete resolution of a target lung lesion and the patient remains active on study. Patient 3 – Confirmed Complete Metabolic ResponseA 44-year-old female with metastatic TNBC who had previously received pembrolizumab/chemotherapy experienced disease progression involving bone and lung metastases in early 2025. Although ineligible for the formal trial due to prior pembrolizumab exposure, the patient was re-treated beginning in June 2025 with pembrolizumab/chemotherapy plus paxalisib (30 mg daily) under physician supervision. On November 10, 2025, FDG PET/CT imaging demonstrated no evidence of active malignancy, consistent with a complete metabolic response. This complete metabolic response was confirmed on follow-up imaging in January 2026, and the patient remains on paxalisib and pembrolizumab therapy. Paxalisib has been generally well tolerated in combination with pembrolizumab and chemotherapy. Approximately 75% of adverse events (AEs) were assessed as unlikely or unrelated to paxalisib. The paxalisib-related AEs were expected and predominantly mild to moderate, consistent with prior studies. At the 30 mg daily dose, one case of Grade 1 hyperglycemia has been observed, requiring no intervention. Two serious adverse events (SAEs) have been reported to date, both deemed unrelated to paxalisib. Following an initial targeted site activation phase designed to ensure rigorous protocol execution and informed by encouraging early clinical signals from the first patients treated, the Company expects to activate two additional clinical sites by April 2026, with two further sites planned for mid-2026. Kazia continues to anticipate the targeted enrollment of twelve TNBC pts target by the end of 2026 and topline data readout in early 2027 Kazia is also evaluating paxalisib in additional breast cancer populations, including earlier-stage TNBC and hormone receptor–positive, HER2-negative (HR+ / HER2-) breast cancer, where dysregulation of the PI3K/mTOR pathway is well established. Paxalisib's oral, once-daily administration offers a potentially convenient treatment option with minimal incremental burden to patients and clinical sites, an important consideration as the Company explores expansion into broader breast cancer populations. The Company will provide updates as these programs advance. "While these observations represent a preliminary read from ongoing studies, the consistency and depth of responses we are seeing including tumor regression across multiple metastatic sites and a complete metabolic response are highly encouraging," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. "Confirmed complete responses in metastatic triple-negative breast cancer are exceedingly rare, particularly in patients who have already progressed on standard therapies. These early data reinforce our belief that paxalisib has the potential to meaningfully enhance the activity of existing immunotherapy-based regimens, and we look forward to generating additional clinical and translational insights throughout the year." For investor and media, please contact Mike Moyer, Managing Director LifeSci Advisors LLC, mmoyer@lifesciadvisors, +1-617-308-4306. About Kazia Therapeutics Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. Forward-Looking Statements This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, the plan to activate additional clinical sites for the Phase 1b study in 2026, the anticipated completion of enrolment in the Phase 1b clinical trial in the fourth quarter of 2026, the anticipated topline data readout in early 2027, the potential of paxalisib's oral, once-daily administration to offer a convenient treatment option with minimal incremental burden to patients and clinical sites, the opportunities of evaluating paxalisib in additional breast cancer populations, and the potential benefits of paxalisib. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia's ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- For decades, visiting Shanghai meant following a familiar set of stops: the Bund at sunset, a stroll through Yuyuan Garden, perhaps a first glimpse of the skyline from Pudong. Increasingly, though, the city wants travelers to move beyond the checklist — and to describe Shanghai in their own words. That shift is on display in a citywide tourism guide competition launched last November, which invited participants to document how they experience Shanghai, from classic sightseeing routes to more personal, idiosyncratic discoveries. In less than two months, the contest drew more than 8,900 submissions, many of them shared widely online, with related videos and posts viewed hundreds of millions of times. Rather than focusing solely on travel agencies and industry influencers, the competition opened its doors to the public, placing curated itineraries alongside accounts shaped by everyday experiences — neighborhood walks, food discoveries, and encounters that don't always appear in traditional guidebooks. Together, they offered a portrait of a city that is at once well known and still in the process of being rediscovered. The timing is deliberate. As the Lunar New Year approaches, Shanghai has rolled out a dense calendar of events across the city, including thousands of cultural activities and performances, accompanied by seasonal promotions from attractions, hotels, guesthouses, and travel agencies. The aim is less about drawing visitors for a single landmark than about encouraging longer stays and repeat visits, particularly during one of China's busiest travel periods. What emerges from these efforts is a broader recalibration of how the city presents itself to travelers, both from within China and abroad. By encouraging visitors to explore beyond established routes — and to share what they find — Shanghai is betting that personal stories can carry more weight than official narratives. In doing so, the city is aligning itself with a wider shift in global travel, where tourists increasingly seek experiences that feel specific, lived-in, and worth retelling. For Shanghai, the hope is that these stories linger well beyond the trip itself, shaping how the city is remembered — and why travelers choose to return.
A12 藝術空間
Food
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
